BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 31747476)

  • 1. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
    Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.
    Kimura T; Takeda A; Tsurugai Y; Kawano R; Doi Y; Oku Y; Hioki K; Miura H; Nagata Y
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1265-1275. PubMed ID: 32712256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.
    Qiu H; Moravan MJ; Milano MT; Usuki KY; Katz AW
    J Gastrointest Cancer; 2018 Dec; 49(4):463-469. PubMed ID: 28710606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
    Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.
    Yeung R; Beaton L; Rackley T; Weber B; Hamm J; Lee R; Camborde M; Pearson M; Duzenli C; Loewen SK; Liu M; Ma R; Schellenberg D
    Clin Oncol (R Coll Radiol); 2019 Jun; 31(6):365-373. PubMed ID: 30792051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
    Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
    BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
    J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.
    Kibe Y; Takeda A; Tsurugai Y; Eriguchi T
    Acta Oncol; 2020 Aug; 59(8):888-894. PubMed ID: 32216593
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma.
    Kim JW; Kim DY; Han KH; Seong J
    Dig Liver Dis; 2019 Mar; 51(3):445-451. PubMed ID: 30503296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.
    Kim JW; Seong J; Lee IJ; Woo JY; Han KH
    Oncotarget; 2016 Jun; 7(26):40756-40766. PubMed ID: 27213593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
    Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
    Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas - A Single Institution Phase II Study.
    Beaton L; Dunne EM; Yeung R; Rackley T; Weber B; Mar C; Yong-Hing CJ; Yoshida EM; DeVries K; Lee R; Duzenli C; Loewen SK; Liu M; Schellenberg D; Ma R
    Clin Oncol (R Coll Radiol); 2020 Jul; 32(7):423-432. PubMed ID: 32093876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
    Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
    Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
    BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.
    Sanuki N; Takeda A; Oku Y; Mizuno T; Aoki Y; Eriguchi T; Iwabuchi S; Kunieda E
    Acta Oncol; 2014 Mar; 53(3):399-404. PubMed ID: 23962244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated SBRT for in- and out-of-field recurrences in the liver.
    Gkika E; Strouthos I; Kirste S; Adebahr S; Schultheiss M; Bettinger D; Fritsch R; Brass V; Maruschke L; Neeff HP; Lang SA; Nestle U; Grosu AL; Brunner TB
    Strahlenther Onkol; 2019 Mar; 195(3):246-253. PubMed ID: 30353350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
    Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
    Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities.
    Que JY; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
    Radiat Oncol; 2014 May; 9():120. PubMed ID: 24885086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.